Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 4/20 | 0.33 |
| ▸ | FDPS | P14324 | 4/20 | 0.32 |
| ▸ | CCR2 | P41597 | 1/20 | 0.32 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.31 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19508343 | 0.98 | ALDH1A1 (0.41) | NPC1ALDH1A1L3MBTL1KMT2AKDM4E | |
| SCHEMBL21745699 | 0.98 | ALDH1A1 (0.41) | NPC1ALDH1A1L3MBTL1KMT2AKDM4E | |
| SCHEMBL23436811 | 0.97 | ALDH1A1 (0.42) | NPC1ALDH1A1L3MBTL1KMT2AKDM4E | |
| SCHEMBL20126492 | 0.97 | ALDH1A1 (0.42) | NPC1ALDH1A1L3MBTL1KMT2AKDM4E | |
| SCHEMBL19157284 | 0.97 | ALDH1A1 (0.42) | NPC1ALDH1A1L3MBTL1KMT2AKDM4E | |
| SCHEMBL19277653 | 0.97 | ALDH1A1 (0.42) | NPC1ALDH1A1L3MBTL1KMT2AKDM4E | |
| SCHEMBL5617171 | 0.92 | NPC1 (0.39) | NPC1ALDH1A1L3MBTL1KMT2AKDM4E | |
| SCHEMBL6077509 | 0.90 | ALDH1A1 (0.40) | NPC1ALDH1A1L3MBTL1KMT2AKDM4E | |
| SCHEMBL18473550 | 0.90 | ALDH1A1 (0.40) | NPC1ALDH1A1L3MBTL1KMT2AKDM4E | |
| SCHEMBL9569047 | 0.90 | ALDH1A1 (0.40) | NPC1ALDH1A1L3MBTL1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220008549-A1 | NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-01-13 | — | — | US | disclosed |
| US-10751346-B2 | Pyrrolobenzodiazepine—anti-PSMA antibody conjugates | MEDIMMUNE LIMITED (GB) | 2020-08-25 | — | — | US | disclosed |
| US-10576164-B2 | Pyrrolobenzodiazepines and conjugates thereof | MEDIMMUNE LIMITED (GB) | 2020-03-03 | — | — | US | disclosed |
| US-20180125997-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MEDIMMUNE LIMITED (GB) | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10576164-B2 | Pyrrolobenzodiazepines and conjugates thereof | CHRM1, NPSR1, CHRM4 | NPC1 1249/4885ALDH1A1 1949/4885L3MBTL1 1229/4885 |
| US-20220008549-A1 | NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF | STING1, CGAS, TLR9 | NPC1 1319/4885ALDH1A1 4336/4885L3MBTL1 3508/4885 |
| US-20180125997-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | CHRM1, NPSR1, CHRM4 | NPC1 1250/4885ALDH1A1 1940/4885L3MBTL1 1229/4885 |
| US-10751346-B2 | Pyrrolobenzodiazepine—anti-PSMA antibody conjugates | PSMA2, PSMA7, FOLH1 | NPC1 3370/4885ALDH1A1 2424/4885L3MBTL1 2347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.